Coulter Partners secures CEO Placement for NeoPhore

London, January 23, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for NeoPhore Limited and is pleased to announce the placement of Michael Shih as Chief Executive Officer (CEO) and Board of Director.

NeoPhore, a small molecule neoantigen immuno-oncology company, is developing a pipeline of highly validated, first-in-class small molecule drugs targeting proteins across the DNA mismatch repair (MMR) pathway to improve the efficacy and durability of revolutionary immunotherapies to treat cancer.

Michael Shih is a highly experienced business development executive with nearly 20 years of success in driving strategic growth. He has a proven track record in leading and executing successful business development transactions, including licensing, mergers & acquisitions, and strategic collaborations.

Robert James, Chairman of the Board, NeoPhore, said:

Michael joins at an exciting stage in NeoPhore’s development having raised a significant Series B financing round which was supported by Bristol Myers Squibb. As we move closer to being a clinical Company, Michael’s experience as a corporate development leader in pharma and biotech will be instrumental in driving NeoPhore’s next phase of growth.

Michael Shih, newly appointed Chief Executive Officer and Board of Director, NeoPhore commented:

NeoPhore’s differentiated approach to targeting the MMR pathway has huge potential to treat cancer. I am looking forward to working with the highly experienced NeoPhore team, who are all clearly aligned to advance the Company’s pipeline.